M

Serial Number 79225539
Registration 5663397
700

Registration Progress

Application Filed
Dec 1, 2017
Under Examination
Approved for Publication
Nov 13, 2018
Published for Opposition
Nov 13, 2018
Registered
Jan 29, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-01-29)
Due: Jan 29, 2025 Overdue

Basic Information

Serial Number
79225539
Registration Number
5663397
Filing Date
December 1, 2017
Registration Date
January 29, 2019
Published for Opposition
November 13, 2018
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 29, 2019
Registration
Registered
Classes
005 041 042

Rights Holder

MAAT PHARMA

99
Address
70 Avenue Tony Garnier
F-69007 Lyon
FR

Ownership History

MAAT PHARMA

Original Applicant
99
FR

MAAT PHARMA

Owner at Publication
99
FR

MAAT PHARMA

Original Registrant
99
FR

Legal Representation

Attorney
Jeffrey H. Greger, Esq.

USPTO Deadlines

Next Deadline
1301 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2019-01-29)
Due Date
January 29, 2029
Grace Period Ends
July 29, 2029

Application History

30 events
Date Code Type Description
Jun 25, 2025 ES71 I TEAS SECTION 71 RECEIVED
Jan 29, 2024 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 21, 2023 NREP P NEW REPRESENTATIVE AT IB RECEIVED
Dec 15, 2022 ADCH M CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 26, 2019 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB
May 20, 2019 FIMP P FINAL DISPOSITION PROCESSED
May 20, 2019 FICS P FINAL DISPOSITION NOTICE SENT TO IB
Apr 29, 2019 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 29, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER
Nov 23, 2018 GPNX P NOTIFICATION PROCESSED BY IB
Nov 13, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 13, 2018 PUBO A PUBLISHED FOR OPPOSITION
Oct 24, 2018 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 24, 2018 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 24, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 26, 2018 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 25, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 25, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 25, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 10, 2018 FINT P FINAL DECISION TRANSACTION PROCESSED BY IB
May 19, 2018 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 20, 2018 RFNT P REFUSAL PROCESSED BY IB
Mar 26, 2018 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 26, 2018 RFRR P REFUSAL PROCESSED BY MPU
Mar 20, 2018 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 19, 2018 CNRT R NON-FINAL ACTION WRITTEN
Mar 14, 2018 DOCK D ASSIGNED TO EXAMINER
Feb 2, 2018 MAFR O APPLICATION FILING RECEIPT MAILED
Jan 29, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 25, 2018 SDRC M SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

Detailed Classifications

Class 005
Pharmaceutical and veterinary products, namely, preparations for the treatment of gut dysbiosis related diseases; food supplements for humans and animals; dietary supplements for humans and animals, namely, nutritional supplements; dietary supplements for humans and animals, namely, dietetic food and beverages for medical or veterinary use; chemical preparations for medical or pharmaceutical use, namely, for the treatment of gut dysbiosis related diseases; chemical preparations for pharmaceutical or medical use, namely, microbiotherapy preparations for the repair of intestinal microbiome; bacteriological preparations for medical or veterinary use; bacterial preparations for medical or veterinary use; biological preparations for medical or veterinary use, namely for the treatment of gut dysbiosis related diseases; culture media for bacteriology; chemico-pharmaceutical preparations, namely, for the treatment of gut dysbiosis related diseases; microbiotherapy preparations for medical use for the repair of intestinal microbiome
Class 041
Education, namely classes, seminars, workshops, in the field of, microbiotherapy, bacteriology, gut microbiota and microbiome-based drugs; training in the field of microbiotherapy, bacteriology, gut microbiota and microbiome-based drugs; training, namely, organization and conducting of colloquiums, conferences, congresses, seminars in the field of microbiotherapy, bacteriology, gut microbiota and microbiome-based drugs; education, namely, arranging of exhibitions for educational purposes; training, namely, arranging and conducting workshops in the field of microbiotherapy, bacteriology, gut microbiota and microbiome-based drugs; training in the field of microbiotherapy
Class 042
Evaluations and assessments in the fields of science and technology provided by engineers; scientific and technical research in the field of biomarkers, nutrition, microbiotherapy, bacteriotherapy, and therapies meant to have an effect on the gut microbiota functions; research and development of new products for others; technical project studies namely, engineering services in the nature of technical project planning for the manufacture, control and traceability of pharmaceutical products having an effect on gut microbiota or biomarkers aiming at characterizing the gut microbiota; chemical analysis; chemistry services namely, laboratory research in the field of chemistry; conducting clinical trials for others; surveying engineering work; scientific laboratory services; research in biology, bacteriology, chemistry and physics; scientific research in the field of microbiotherapy

Additional Information

Design Mark
The mark consists of a letter "M" with a stylized depiction of a feather appearing to the left.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 041 042